The precision medicine revolution has led to the development and US FDA approval of
multiple targeted therapies in non-squamous non-small cell lung cancers, including tyrosine …

Simple Summary This study investigated the relationship between erlotinib resistance and
stemness in lung adenocarcinoma. NCAPG2 was identified as an erlotinib resistance gene …

Introduction Multiple genetic mechanisms have been identified in EGFR-mutant lung
cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) …

Genomically amplified fibroblast growth factor receptor 1 (FGFR1) is an oncogenic driver in
defined lung cancer subgroups and predicts sensibility against FGFR1 inhibitors in this …

© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016; 8 (11): E1528-E1531
jtd. amegroups. com other miR-200c targets and potentially other ZEB1 target genes or …

Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both
EGFR-activating and EGFR inhibitor–resistant T790M mutations more potently than wild …

Inherent or acquired resistance to sotorasib poses a substantialt challenge for NSCLC
treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells …

Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the
clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple …

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) protein
serve as a critical pillar in the treatment of non-small cell lung cancer (NSCLC), but …